66376-36-1
66376-36-1
Chemical Structure
Alendronic acid
- CAS No.: 66376-36-1
- Formula:C4H13NO7P2
- Molecular Weight:249.10
IUPAC Name: (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
InChIKey: OGSPWJRAVKPPFI-UHFFFAOYSA-N
SMILES: OC(P(O)(O)=O)(CCCN)P(O)(O)=O
Biological Activity: Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Alendronic acid | ≥98.0% | Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alendronic acid-d6 | 98.0% | Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681-688. [Content Brief]
- [2]. Sharpe M, et al. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Content Brief]
- [3]. de Campos WG, et al. Alendronate induces skeletal alterations in the chicken embryonic development model. Toxicol Appl Pharmacol. 2023 Oct 1;476:116673. [Content Brief]
Keywords
